11,089 Shares in Danaher Corporation $DHR Bought by Park State Asset Management

Park State Asset Management bought a new position in Danaher Corporation (NYSE:DHR) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,089 shares of the conglomerate’s stock, valued at approximately $2,112,000. Danaher accounts for about 2.1% of Park State Asset Management’s holdings, making the stock its 15th biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Danaher during the second quarter valued at $10,492,520,000. Norges Bank bought a new position in shares of Danaher during the fourth quarter valued at $2,177,106,000. Bank of New York Mellon Corp purchased a new stake in shares of Danaher during the second quarter valued at $712,875,000. Viking Global Investors LP boosted its position in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after buying an additional 2,455,994 shares during the last quarter. Finally, Deutsche Bank AG bought a new stake in Danaher in the 2nd quarter worth about $446,265,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on DHR. DZ Bank began coverage on Danaher in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 target price for the company. Argus dropped their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. TD Cowen reduced their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Guggenheim decreased their price objective on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Finally, Stifel Nicolaus lowered their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Stock Performance

Shares of DHR opened at $199.62 on Wednesday. The business has a 50-day simple moving average of $193.74 and a two-hundred day simple moving average of $192.50. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a market cap of $140.33 billion, a price-to-earnings ratio of 35.46, a PEG ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 EPS. On average, analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.